VEGFA and glioblastoma: Anti-angiogenic therapies like bevacizumab, a VEGF (vascular endothelial growth factor receptor) inhibitor, are FDA-approved, but their impact on overall survival remains modest, likely due to compensatory pathways [114] and the presence of different molecular subtypes of GBM [115].